Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenlabs EthicaBOM:530697 +4.97%55 Return-on-Tangible-Equity is 0.05% as of Mar. 2026, which is 99% below its 10-year median of 6.94. GuruFocus rates BOM:530697 with a GF Score™ of 55/100 and a GF Value™ of ₹29.10 (Fairly Valued). The stock has 3 warning signs investors should review. Among 112 Medical Distribution companies, Zenlabs Ethica ranks worse than 90.18% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Zenlabs Ethica's annualized net income for the quarter that ended in Mar. 2026 was ₹0.0 Mil. Zenlabs Ethica's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹85.1 Mil. Therefore, Zenlabs Ethica's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.05%.
The historical rank and industry rank for Zenlabs Ethica's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530697'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -20.44 Med: 6.94 Max: 18.18
Current: -19.69
During the past 13 years, Zenlabs Ethica's highest Return-on-Tangible-Equity was 18.18%. The lowest was -20.44%. And the median was 6.94%.
BOM:530697's Return-on-Tangible-Equity is ranked worse than 90.18% of 112
companies
in the Medical Distribution industry
Industry Median: 8.755
vs BOM:530697: -19.69
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zenlabs Ethica Return-on-Tangible-Equity Related Terms
Zenlabs Ethica Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530697 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Zenlabs Ethica's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.05% mean?
Zenlabs Ethica (BOM:530697) has a Return-on-Tangible-Equity of 0.05% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zenlabs Ethica and its competitors. This is 99% below median its historical median of 6.94. According to the industry distribution chart, Zenlabs Ethica ranks #101 out of 112 companies in the Medical Distribution industry, placing it in the top 90.2%.
Is Zenlabs Ethica's Return-on-Tangible-Equity too high?
Zenlabs Ethica's current Return-on-Tangible-Equity of 0.05% is 99% below median its 10-year median of 6.94. The Medical Distribution industry median Return-on-Tangible-Equity is 8.76. Zenlabs Ethica's value of 0.05% is 99.4% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #101 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #101 out of 112 companies for Return-on-Tangible-Equity. This places Zenlabs Ethica in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.76. Zenlabs Ethica's value of 0.05% is 99.4% below this benchmark. While the company's 10-year median is 6.94 vs. the industry median of 8.76, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.76, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current Return-on-Tangible-Equity of 0.05% is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current Return-on-Tangible-Equity is 0.05%, which is 99% below median its own 10-year median of 6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Fairly Valued. The stock's GF Value™ is ₹29.10, compared to a current price of ₹28.92 — trading 0.6% below its estimated fair value. The current Return-on-Tangible-Equity is 0.05%, which is 99% below median its 10-year median of 6.94 and 99.4% below the Medical Distribution industry median of 8.76. Zenlabs Ethica's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current Return-on-Tangible-Equity is 0.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be undervalued.
The current stock price of ₹28.92 is trading 0.6% below its estimated GF Value™ of ₹29.10.
GuruFocus considers Zenlabs Ethica to be Fairly Valued.
Key valuation signals for BOM:530697:
Return-on-Tangible-Equity: 0.05% (99% below median its 10-year median of 6.94)
GF Value™: ₹29.10 vs. price of ₹28.92 (0.6% below fair value)
Industry Position: 99.4% below the Medical Distribution median (#101 of 112)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
55GF Score
Get the complete analysis for BOM:530697
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
